Randomized phase 2 study of bone‐targeted therapy containing strontium‐89 in advanced castrate‐sensitive prostate cancer

CONCLUSIONSThe data showed that bone‐targeted therapy using 1 dose of Sr‐89 combined with chemohormonal ablation therapy did not favorably affect the PFS of patients with castrate‐sensitive prostate cancer. The combined therapy was feasible and safe. Whether such bone‐targeted therapy provides a favorable outcome for those patients with a greater tumor burden in the bone warrants further investigation. Cancer 2014. © 2014 American Cancer Society.

Source: Cancer - August 22, 2014 Category: Cancer & Oncology Authors: Mehmet Asim Bilen, Marcella M. Johnson, Paul Mathew, Lance C. Pagliaro, John C. Araujo, Ana Aparicio, Paul G. Corn, Nizar M. Tannir, Franklin C. Wong, Michael J. Fisch, Christopher J. Logothetis, Shi‐Ming Tu Tags: Original Article Source Type: research